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COVID-19: where have the
lymphocytes gone?
One of the predominant features of coronavirus dis-
ease 2019 (COVID-19) is absolute lymphopenia,
which is relevant in clinical phases immediately pre-
ceding the deterioration of respiratory function and
the need for oxygen supply or assisted ventilation.1
Homing or chemiotaxis phenomena should help to
understand the possible pathogenetic significance of
lymphopenia, perhaps as a sign of incipient interstitial
lymphocytic pneumonia. Interestingly, in Severe
Acute Respiratory Syndrome (SARS) animal models,
lung inflammation intensified after viral clearance,
with a peak around 14 days after infection.1,2 Similar
observations have been made in SARS patients, raising
the question of whether the damage could be caused
by uncontrolled viral replication or uncontrolled
immune responses.1,2
Postmortem biopsies in COVID-19 subjects indicate
that in early stages a lymphocytic alveolar or interstitial
pattern is observed, giving way later to acute fibrinous
organising pneumonia culminating in diffuse alveolar
damage.3–5
In light of these findings, we speculated that steroids
with prominent lympholytic activity, such as high-dose
dexamethasone, could be useful in decreasing the clinical
manifestations and severity of interstitial pneumonia if
administered within the time frame of incipient and
evolving lymphopenia, that is, before the onset of respira-
tory function deterioration. We administered high-dose
dexamethasone to 79 patients (Table 1), who accounted
for 39.2% of cases in our hospital from 22 February to
11 March 2020, before individualising steroid treatment
following the World Health Organization recommenda-
tion.6 Steroid treatment was usually administered along
with antiretrovirals; no antibiotics were given except in
cases of procalcitonin increase.
As the data on autopsy findings in COVID-19 are
scarce, the main question remains: where did the
lymphocytes go? If there is no lymphocytic interstitial
pneumonia, then there is no reason to investigate hom-
ing or chemiotaxis phenomena. In a study based on
postmortem core biopsies, where the time from disease
onset to death ranged 15–52 days, all patients had
lymphocytopenia, except for one patient with leukae-
mia.4 In patients with lymphocytopenia, postmortem
histology showed diffuse alveolar damage with injury to
the alveolar epithelial cells, hyaline membrane forma-
tion, and hyperplasia of type II pneumocytes. In another
study with two autopsies, diffuse alveolar damage and
airway inflammation suggested a true virus-related
pathology.5 If it is true that there are many endothelial
cells in the bloodstream, it is unclear why there are mac-
rophages and no lymphocytes in the interstitium.
SARS-CoV-2 is a deceptive virus, and COVID-19 is a
deceptive disease. The immunological key to understand-
ing many of its clinical features may well be the
lymphopenia. As a next step in research, it is important to
find out where the deceptive journey of lymphocytes is.
Is there a systemic or virological reason for lymphopenia?
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Table 1 Clinical outcomes in COVID-19 patients treated with steroids (S/s)
Outcomes in the steroid group
Total (steroid) 201 (79)
Male/female 63/16
Median age (range) (years) 59 (33–87)
No. survivors (%) 71 (89.8)
Death within 7 days from S/s onset 4 (5.0)
Death within 14 days from S/s onset 0 (0)
Death within 28 days from S/s onset 4 (5.0)
General correspondence
Internal Medicine Journal 50 (2020) 1436–1437
© 2020 Royal Australasian College of Physicians
1436
Autopsies, Oklahoma, USA. Am J Clin
Pathol 2020; 153: 725–33.
6 World Health Organization. WHO
Director-General’s Opening Remarks at
the Media Briefing on COVID-19 [cited





Internal Medicine Journal 50 (2020) 1437–1438
© 2020 Royal Australasian College of Physicians
1437
Letters to the Editor
